Understand your risk. Make informed decisions. Advocate for yourself. Support the research.
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
The management of HDGC family members is critical and complex. The following summarizes the most recent HDGC Clinical Guideline update. The 2015 guideline document and related supplemental protocols are provided here. The HDGC Clinical Guidelines – Commentary page is organized to match each major section of the guideline document. Follow each link to view more detailed information covering each section of the guideline.
The IGCLC group will reconvene in March 2019 to update the guideline.
The 2nd Consensus meeting on Hereditary Gastric Cancer was held at the Radboud University Medical Centre in Nijmegen, The Netherlands in March of 2014. The workshop, led by a group of clinical geneticists, gastroenterologists, surgeons, oncologists, pathologists, molecular biologists, dietician and patients representatives from nine different countries, convened in order to update the management guidelines for this condition last set in 2010 and to propose direction for future research.
The group’s goal while there was to make important updates and changes to the current consensus guidelines for HDGC.
Workshop discussions were focused on five major topics:
- Genetic counseling and mutation analysis
- Endoscopic surveillance and screening of cancer
- Risk reduction surgery of the stomach and breasts
- Pathological specimen processing and diagnosis
- Patients’ and dietician perspective
Updates and new areas addressed in the latest guideline include:
- Updated cancer risks for CDH1 mutation carriers
- Broadened criteria for genetic testing
- Genetic testing lab perspective
- Panel sequencing
- Psychosocial effects of counseling
- Pregnancy and assisted reproduction
- Post-gastrectomy symptoms and treatment options
- Post-surgical care and nutrition
- Patient advocacy and the next steps in patient care and HDGC research
In 2015 the updated HDGC guideline was published in the Journal of Medical Genetics along with two supplemental protocols. They are:
- Endoscopy protocol for HDGC
- Protocol and reporting of CDH1 mutation-related gastrectomy specimens
History of HDGC and the IGCLC
In 1964, gastric cancer was noted in a Maori tribal family in New Zealand, following an autosomal dominant pattern of inheritance. CDH1 gene mutations were first identified in patients from three Maori families in 1998. At this time, the IGCLC was formed (see below) and the name “Hereditary Diffuse Gastric Cancer” was introduced.
The International Collaborative Group on Hereditary Gastric Cancer (ICG-HGC) was founded in April 1999 in Seoul, South Korea, during the 3rd International Gastric Cancer Congress. The ICG-HGC was established to define the clinical criteria for hereditary gastric cancer, to develop strategies for the management of affected families, and to promote international collaborative studies. The inaugural meeting of the ICG-HCG was held in Seoul on August 22, 1999, with 110 participants from six countries. Coincident with the organization of the ICG-HCG, the International Gastric Cancer Linkage Consortium (IGCLC) hosted its first workshop in Cambridge, UK in June 1999. The consensus statements published as an “overview and guideline for management”. Because the aims of these two independent groups were concordant, they have merged under the IGCLC designation.
The 1st Consensus meeting of the IGCLC on Hereditary Gastric Cancer was held at the Cambridge Research Institute, Cambridge UK in 2008 to update the management guidelines originally set in 1999. These updated guidelines were published in 2010.